Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.
Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma (LBCL) or follicular lymphoma.
Data from the phase 1 ALPHA clinical trial (NCT03939026) showed evidence of clinical activity with ALLO-647 and selective lymphodepletion with ALLO-501 in this patient population.
Additionally, the agents demonstrated a manageable safety profile, says Neelapu. Moreover, no dose-limiting toxicities, graft-versus-host disease, or immune effector cell–associated neurotoxicity syndrome was observed in the study.
Cytokine release syndrome (CRS) occurred in 32% of patients overall, with only 1 case of grade 3 CRS, explained Neelapu.
While expected, half of the patients treated experienced infusion-related reactions due to ALLO-647, says Neelapu. However, these adverse events did not lead to dose interruption of ALLO-501 and were reversible.
Other toxicities included reversible infections that were identified during routine weekly monitoring, concludes Neelapu.